JP2023512843A5 - - Google Patents

Info

Publication number
JP2023512843A5
JP2023512843A5 JP2022548412A JP2022548412A JP2023512843A5 JP 2023512843 A5 JP2023512843 A5 JP 2023512843A5 JP 2022548412 A JP2022548412 A JP 2022548412A JP 2022548412 A JP2022548412 A JP 2022548412A JP 2023512843 A5 JP2023512843 A5 JP 2023512843A5
Authority
JP
Japan
Prior art keywords
ivabradine
amiodarone
pharmaceutical product
administration
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022548412A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512843A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/017220 external-priority patent/WO2021163037A1/en
Publication of JP2023512843A publication Critical patent/JP2023512843A/ja
Publication of JP2023512843A5 publication Critical patent/JP2023512843A5/ja
Pending legal-status Critical Current

Links

JP2022548412A 2020-02-10 2021-02-09 移植後不整脈を治療および予防する方法 Pending JP2023512843A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062972330P 2020-02-10 2020-02-10
US62/972,330 2020-02-10
PCT/US2021/017220 WO2021163037A1 (en) 2020-02-10 2021-02-09 Methods of treating and preventing engraftment arrhythmias

Publications (2)

Publication Number Publication Date
JP2023512843A JP2023512843A (ja) 2023-03-29
JP2023512843A5 true JP2023512843A5 (https=) 2024-07-02

Family

ID=77291628

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548412A Pending JP2023512843A (ja) 2020-02-10 2021-02-09 移植後不整脈を治療および予防する方法

Country Status (11)

Country Link
US (1) US20230077983A1 (https=)
EP (1) EP4103206A4 (https=)
JP (1) JP2023512843A (https=)
KR (1) KR20220140532A (https=)
CN (1) CN115484966A (https=)
AU (1) AU2021218653A1 (https=)
BR (1) BR112022015768A2 (https=)
CA (1) CA3166678A1 (https=)
IL (1) IL295236A (https=)
MX (1) MX2022009807A (https=)
WO (1) WO2021163037A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3979997A1 (en) * 2019-06-06 2022-04-13 Novo Nordisk A/S Application of antiarrhythmic agents to stem cell derived cardiomyocytes and uses thereof
US20230250393A1 (en) * 2022-02-09 2023-08-10 University Of Washington Pre-treating cardiomyocytes with anti-arrhythmic drugs to reduce engraftment arrhythmia
WO2023173123A1 (en) * 2022-03-11 2023-09-14 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
EP4593821A2 (en) * 2022-09-28 2025-08-06 Bluerock Therapeutics LP Compositions and methods for treating graft-related arrhythmia
WO2025137525A1 (en) * 2023-12-22 2025-06-26 Bluerock Therapeutics Lp Molecular identification of cardiomyocytes for cardiac cell therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG192305A1 (en) * 2012-01-20 2013-08-30 Singapore Health Serv Pte Ltd Induced pluripotent stem cell (ipsc)-derived cardiomyocyte-like cells and uses thereof in screening for agents
US9994812B2 (en) * 2012-04-04 2018-06-12 University Of Washington Through Its Center For Commercialization Systems and method for engineering muscle tissue
US9855317B2 (en) * 2015-04-27 2018-01-02 Reflex Medical, Inc. Systems and methods for sympathetic cardiopulmonary neuromodulation
AU2018235964A1 (en) * 2017-03-15 2019-08-15 Cambridge Enterprise Limited Methods and compositions for enhancing cardiomyocyte maturation and engraftment
EP3979997A1 (en) * 2019-06-06 2022-04-13 Novo Nordisk A/S Application of antiarrhythmic agents to stem cell derived cardiomyocytes and uses thereof

Similar Documents

Publication Publication Date Title
JP2023512843A5 (https=)
US10660880B2 (en) Dosing regimen for a selective S1P1 agonist
JP2011518785A (ja) 心血管入院または死亡の予防に用いる薬剤を調製するためのドロネダロンの使用
WO2014082514A1 (zh) 一种启动哺乳动物干细胞的方法及二氧化氯在制备用于启动哺乳动物干细胞的药物的应用
WO2021068802A1 (zh) Nadh 及其盐和 / 或 nmn 在制备肌肉增强或抑制肌肉量下降的药物或保健品中的应用
CN112438976B (zh) 一种具有肾脏保护作用的药物组合物
Wilting et al. QTc prolongation and torsades de pointes in an elderly woman taking fluoxetine
AU2017365926B2 (en) Treatments for heart failure and cardiac ischaemic reperfusion injury
CN107303390A (zh) Dpp4抑制剂在制备治疗低氧性肺动脉高压药物中的用途
CN108721294A (zh) 化合物epz5676及其相关抑制剂在制备治疗心肌纤维化疾病药物中的用途
US20250375405A1 (en) N-lactoyl-phenylalanine for preventing and/or treating ischemic heart disease and method for preventing and/or treating ischemic heart disease
WO2007048352B1 (en) Pharmaceutical composition and method for regenerating myofibers in the treatment of muscle injuries
CN119564692A (zh) 利匹韦林在制备治疗心肌梗死药物中的应用
Hamid et al. Effect of single dose magnesium on arrhythmias in patients undergoing coronary artery bypass surgery
WO2023185085A1 (zh) Pd1抑制剂在制备心脏成纤维细胞转分化抑制剂中的用途
CN103203009B (zh) 一种五肽的部分代谢物用于制备抗心肌缺血产品的新用途
Resnekov et al. Sustained-release quinidine (Kinidin Durules) in maintaining sinus rhythm after electroversion of atrial dysrhythmias
CN105833001B (zh) 参芪降糖颗粒在制备糖尿病性心脏病药物中的用途
Rampton Hypertensive crisis in a patient given sinemet, metoclopramide, and amitriptyline
WO2011141872A1 (en) Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality in patients having a first recurrence of atrial fibrillation or atrial flutter
TWI629991B (zh) 牛樟芝在防治心肌肥大及心肌纖維化中的應用
Chowdhury et al. The SGLT2 inhibitor empagliflozin reduces mortality in experimental pulmonary hypertension
RU2822010C1 (ru) Способ терапии сердечно-сосудистого заболевания
CN102085208B (zh) 一种治疗冠心病、心绞痛的药物组合物
CN109364050A (zh) 艾地苯醌在制备治疗肺动脉高压药物中的应用